Enanta Pharmaceuticals, Inc.

NasdaqGS ENTA

Enanta Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -9.77

Enanta Pharmaceuticals, Inc. Interest Coverage Ratio is -9.77 for the Trailing 12 Months (TTM) ending September 30, 2024, a 60.05% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Enanta Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -24.45.
Enanta Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -201.05, a -1,843.93% change year over year.
Enanta Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -10.34, a -401.34% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGS: ENTA

Enanta Pharmaceuticals, Inc.

CEO	Dr. Jay R. Luly Ph.D.
IPO Date	March 21, 2013
Location	United States
Headquarters	500 Arsenal Street
Employees	145
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years